Here’s what you should know.
1. TheStreet joins several other analysts in downgrading the industry giant.
2. Yet, despite the recent downgrades, Boston Scientific still has 13 “buy” ratings, six “hold” ratings and a single “sell” rating.
3. Analysts attached an average price target of $31.06 per share to the stock.
More articles on supply chain:
Riverside Regional Surgery Center owner, 3 others charged in $8M healthcare fraud scheme: 5 things to know
ASC physician and equity ownership preferences — 14 statistics
What ASCs can do to reduce SSI
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.